Literature DB >> 8423216

High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.

J A Fagin1, K Matsuo, A Karmakar, D L Chen, S H Tang, H P Koeffler.   

Abstract

The development and progression of thyroid tumors is signaled by phenotype-specific mutations of genes involved in growth control. Molecular events associated with undifferentiated thyroid cancer are not known. We examined normal, benign, and malignant thyroid tissue for structural abnormalities of the p53 tumor suppressor gene. Mutations were detected by single-strand conformation polymorphisms of PCR-amplified DNA, using primers bracketing the known hot spots on either exons 5, 6, 7, or 8. The prevalence of mutations was as follows: normal thyroid 0/6; follicular adenomas 0/31; papillary carcinomas 0/37; medullary carcinomas 0/2; follicular carcinomas 1/11; anaplastic carcinomas 5/6; thyroid carcinoma cell lines 3/4. Positive cases were confirmed by direct sequencing of the PCR products. All five anaplastic carcinoma tissues and the anaplastic carcinoma cell line ARO had G:C to A:T transitions leading to an Arg to His substitution at codon 273. In both tumors and cell lines, examples of heterozygous and homozygous p53 mutations were identified. The only thyroid carcinoma cell line in which p53 mutations were not detected in exons 5-8 had markedly decreased p53 mRNA levels, suggesting the presence of a structural abnormality of either p53 itself or of some factor controlling its expression. The presence of p53 mutations almost exclusively in poorly differentiated thyroid tumors and thyroid cancer cell lines suggests that inactivation of p53 may confer these neoplasms with aggressive properties, and further loss of differentiated function.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8423216      PMCID: PMC330012          DOI: 10.1172/JCI116168

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  45 in total

Review 1.  p53 mutations: gains or losses?

Authors:  D Michalovitz; O Halevy; M Oren
Journal:  J Cell Biochem       Date:  1991-01       Impact factor: 4.429

2.  T antigen is bound to a host protein in SV40-transformed cells.

Authors:  D P Lane; L V Crawford
Journal:  Nature       Date:  1979-03-15       Impact factor: 49.962

3.  Characterization of the human p53 gene.

Authors:  P Lamb; L Crawford
Journal:  Mol Cell Biol       Date:  1986-05       Impact factor: 4.272

4.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity.

Authors:  A P Feinberg; B Vogelstein
Journal:  Anal Biochem       Date:  1983-07-01       Impact factor: 3.365

5.  Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells.

Authors:  D I Linzer; A J Levine
Journal:  Cell       Date:  1979-05       Impact factor: 41.582

6.  Molecular cloning and in vitro expression of a cDNA clone for human cellular tumor antigen p53.

Authors:  E Harlow; N M Williamson; R Ralston; D M Helfman; T E Adams
Journal:  Mol Cell Biol       Date:  1985-07       Impact factor: 4.272

7.  Carcinogenic epoxides of benzo[a]pyrene and cyclopenta[cd]pyrene induce base substitutions via specific transversions.

Authors:  E Eisenstadt; A J Warren; J Porter; D Atkins; J H Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

8.  Purification of biologically active globin messenger RNA by chromatography on oligothymidylic acid-cellulose.

Authors:  H Aviv; P Leder
Journal:  Proc Natl Acad Sci U S A       Date:  1972-06       Impact factor: 11.205

9.  Isolation and characterization of full-length cDNA clones for human alpha-, beta-, and gamma-actin mRNAs: skeletal but not cytoplasmic actins have an amino-terminal cysteine that is subsequently removed.

Authors:  P Gunning; P Ponte; H Okayama; J Engel; H Blau; L Kedes
Journal:  Mol Cell Biol       Date:  1983-05       Impact factor: 4.272

10.  High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis.

Authors:  N R Lemoine; E S Mayall; F S Wyllie; E D Williams; M Goyns; B Stringer; D Wynford-Thomas
Journal:  Oncogene       Date:  1989-02       Impact factor: 9.867

View more
  138 in total

Review 1.  Expression patterns of cellular growth-controlling genes in non-medullary thyroid cancer: basic aspects.

Authors:  N J Sarlis
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

2.  Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas.

Authors:  K M La Perle; S M Jhiang; C C Capen
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

3.  Establishment and characterization of novel human primary and metastatic anaplastic thyroid cancer cell lines and their genomic evolution over a year as a primagraft.

Authors:  Manoj Garg; Ryoko Okamoto; Yasunobu Nagata; Deepika Kanojia; Subhashree Venkatesan; Anand M T; Glenn D Braunstein; Jonathan W Said; Ngan B Doan; Quoc Ho; Tadayuki Akagi; Sigal Gery; Li-Zhen Liu; Kar Tong Tan; Wee Joo Chng; Henry Yang; Seishi Ogawa; H Phillip Koeffler
Journal:  J Clin Endocrinol Metab       Date:  2014-11-03       Impact factor: 5.958

4.  Amplification of thymosin beta 10 and AKAP13 genes in metastatic and aggressive papillary thyroid carcinomas.

Authors:  Liliána Z Fehér; Gábor Pocsay; László Krenács; Agnes Zvara; Enikő Bagdi; Réka Pocsay; Géza Lukács; Ferenc Győry; Andrea Gazdag; Erzsébet Tarkó; László G Puskás
Journal:  Pathol Oncol Res       Date:  2011-12-11       Impact factor: 3.201

5.  Possible Relation of p53 and mdm-2 Oncoprotein Expression in Thyroid Carcinoma: A Molecular-Pathological and Immunohistochemical Study on Paraffin-Embedded Tissue.

Authors:  Kurt W. Schmid; Agnes Bankfalvi; Swantja Mucke; Dietmar Ofner; Kristina Riehemann; Soren Schroder; Andrea Stucker; Martin Totsch; Barbara Dockhorn-Dworniczak
Journal:  Endocr Pathol       Date:  1996       Impact factor: 3.943

Review 6.  Molecular pathology of thyroid cancer: diagnostic and clinical implications.

Authors:  James A Fagin; Nicholas Mitsiades
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2008-12       Impact factor: 4.690

Review 7.  Deregulation of microRNA expression in thyroid neoplasias.

Authors:  Pierlorenzo Pallante; Sabrina Battista; Giovanna Maria Pierantoni; Alfredo Fusco
Journal:  Nat Rev Endocrinol       Date:  2013-11-19       Impact factor: 43.330

8.  Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.

Authors:  Soeren Latteyer; Vera Tiedje; Katharina König; Saskia Ting; Lukas C Heukamp; Lydia Meder; Kurt Werner Schmid; Dagmar Führer; Lars Christian Moeller
Journal:  Endocrine       Date:  2016-10-01       Impact factor: 3.633

Review 9.  Potential utility and limitations of thyroid cancer cell lines as models for studying thyroid cancer.

Authors:  Tania Pilli; Kanteti V Prasad; Shankar Jayarama; Furio Pacini; Bellur S Prabhakar
Journal:  Thyroid       Date:  2009-12       Impact factor: 6.568

Review 10.  Molecular pathogenesis and mechanisms of thyroid cancer.

Authors:  Mingzhao Xing
Journal:  Nat Rev Cancer       Date:  2013-03       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.